Shares of TherapeuticsMD Inc (NASDAQ:TXMD) have been assigned a consensus recommendation of “Buy” from the thirteen brokerages that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $14.63.
TXMD has been the topic of a number of research reports. Oppenheimer set a $12.00 target price on shares of TherapeuticsMD and gave the stock a “buy” rating in a research note on Wednesday, May 30th. ValuEngine raised shares of TherapeuticsMD from a “hold” rating to a “buy” rating in a research note on Tuesday, May 8th. Noble Financial reaffirmed a “buy” rating on shares of TherapeuticsMD in a research note on Friday, March 9th. Zacks Investment Research raised shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a research note on Wednesday, May 9th. Finally, BidaskClub raised shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a research note on Friday, June 8th.
Get TherapeuticsMD alerts:TherapeuticsMD traded down $0.03, reaching $6.32, during mid-day trading on Tuesday, MarketBeat reports. The stock had a trading volume of 810,000 shares, compared to its average volume of 2,600,899. The stock has a market capitalization of $1.35 billion, a price-to-earnings ratio of -17.19 and a beta of 1.38. TherapeuticsMD has a 12 month low of $4.34 and a 12 month high of $7.66.
TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Thursday, May 3rd. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). The firm had revenue of $3.77 million during the quarter, compared to the consensus estimate of $4.18 million. TherapeuticsMD had a negative net margin of 483.98% and a negative return on equity of 66.77%. The business’s revenue was down 5.4% compared to the same quarter last year. During the same period last year, the business earned ($0.11) earnings per share. sell-side analysts predict that TherapeuticsMD will post -0.51 EPS for the current fiscal year.
Large investors have recently modified their holdings of the company. MANA Advisors LLC acquired a new position in shares of TherapeuticsMD during the fourth quarter worth $104,000. Paloma Partners Management Co acquired a new position in shares of TherapeuticsMD during the fourth quarter worth $105,000. Beaumont Financial Partners LLC acquired a new position in shares of TherapeuticsMD during the first quarter worth $123,000. Xact Kapitalforvaltning AB lifted its holdings in shares of TherapeuticsMD by 96.3% during the first quarter. Xact Kapitalforvaltning AB now owns 31,800 shares of the company’s stock worth $155,000 after purchasing an additional 15,600 shares during the period. Finally, Barclays PLC lifted its holdings in shares of TherapeuticsMD by 33,787.3% during the first quarter. Barclays PLC now owns 37,276 shares of the company’s stock worth $182,000 after purchasing an additional 37,166 shares during the period. Institutional investors own 72.70% of the company’s stock.
About TherapeuticsMD
TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.
No comments:
Post a Comment